Hyaluronic acid and chitosan deliver a range of benefits to promote healing.
hyaluronic acid & chitosan
Hyaluronic acid and chitosan deliver a range of benefits to promote healing.
Hyaluronic acid (HA) is a naturally occurring polysaccharide widely used in ophthalmic products due to its exceptional hydrating and viscoelastic properties. Its ability to retain water makes it highly effective in maintaining ocular surface moisture, providing lubrication, and promoting comfort, particularly in conditions like NK and dry eye disease. HA is biocompatible, non-toxic, and generally well-tolerated, making it safe for use on the cornea. HA’s wound-healing and anti-inflammatory properties contribute to its therapeutic benefits in supporting corneal repair and reducing irritation. HA’s safety and efficacy have been well-documented, making it a trusted component in a wide range of ophthalmic applications.
Chitosan is a natural and versatile biopolymer. It has a range of properties that make it useful in a variety of applications. It’s biocompatibility, biodegradability, and non-toxicity making it a promising material for use in medical applications, while its mucoadhesive, bleeding control, antimicrobial and tissue-regenerative properties enhance the attributes of the products we develop.
- muchoadhesive – enabling drugs to stay in place longer
- accelerates wound healing
- anti-microbial
- non-immunogenic/ biodegradable
for eye care
Hyaluronic acid, is a constituent of multiple ophthalmic products. It has mucoadhesive properties that allow it to cling to mucosal surfaces, including the conjunctival and corneal surfaces of the eye. This assists therapeutic ingredients, in this case, plasma growth factors, in maintaining extended contact with the eye, potentially offering enduring relief. In addition to imparting a positive therapeutic benefit, ECI’s hyaluronic acid helps stabilize growth factors, improving ease of use.
for wound care
Chitosan has been shown to have antibacterial and anti-inflammatory properties and may promote wound healing by stimulating the growth of new tissue and reducing inflammation. Studies have found that chitosan-based wound dressings can accelerate healing and reduce the risk of infection in patients with chronic wounds. Chitosan may be capable of creating a protective layer to help retain moisture and acts as a shield against external irritants.
Chitosan has also been studied for its potential use in a range of other applications, such as as a drug delivery system for antibiotics, as a wound dressing for burns, and as a bioadhesive for surgical applications.
for mucosal membranes
Plasma’s growth factors and proteins promote cell proliferation, tissue regeneration, and repair, potentially making them beneficial for mucosal health. Additionally, the inherent composition of plasma naturally hydrates dry mucosal membranes.
Both hyaluronic acid Chitosan are generally considered safe for human use, with few reported complications.
As with any new therapy, it is important to consult with a healthcare professional before using any chitosan-containing products, especially if you have a history of allergies, digestive problems, or are taking any medications.
learn more about:
human plasma
Platelet-rich plasma is high in growth factors and proteins. These components are known to promote cell proliferation, tissue regeneration, and repair, making them beneficial for mucosal health. Additionally, plasma’s inherent composition naturally hydrates dry mucosal membranes.
our platform
Our platform leverages growth factors derived from donated human platelet-rich plasma and proprietary hyaluronic acid (HA) or chitosan. The tissue-repairing benefits of plasma-derived products, combined with the sustained action and impact of HA or chitosan, may provide relief and long-lasting therapeutic action.
our products
Our therapeutic formulation is suitable for a variety of products, including liquid eye drops, gels, ointments, contact lenses, contoured bandages, and wound dressings. Initially, ECI is pursuing ophthalmic indications for neurotrophic keratopathy (NK) and dry eye disease (DED).
ECI’s pipeline includes indications for ophthalmic burns, epithelial defects, endothelial diseases, limb stem cell deficiency, ocular graft-versus-host disease (GvHD), corneal abrasions, and chronic wounds.